retatrutide clinical trials retatrutide Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and Trial of next-gen weight-loss drug

For men, these treatments are particularly relevant given the links between obesity, low testosterone, cardiovascular risk, and erectile dysfunction

1, 2024, pp

Nurse Annie has developed specialized protocols designed specifically to restore skin elasticity and thickness during rapid weight loss

It must be said that there is no one-size-fits-all diet that must be prescribed when a patient is offered therapy with a GLP-1 or GLP/GIP medication

Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,